Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?

Heidar Sharafi, Seyed Moayed Alavian

Abstract

Treatment of hepatitis C virus (HCV) infection has evolved greatly through the recent decade. The availability of direct-acting antiviral agents (DAAs) targeting the functional proteins of HCV has resulted in the introduction of DAA-based combination therapies, providing an optimal rate of treatment success. Among the DAAs, NS5A inhibitors are used in most of the introduced and approved HCV antiviral regimens. Resistance-associated substitutions (RASs) are amino acid substitutions in HCV protein sequences that result in decreased antiviral efficacy of the HCV DAAs. Among the HCV RASs, the NS5A RASs were found to effectively modify and decrease treatment response to NS5A inhibitor-containing regimens. As a baseline predictor of treatment response, NS5A RAS draws attention for pretreatment testing in targeted patient groups. Given NS5A RASs are either naturally-occurring or DAA-selected, the application of NS5A RAS testing can be considered in two settings of NS5A inhibitor-naïve patients and NS5A inhibitor-experienced patients. Less than 5% of NS5A inhibitor-naïve patients harbor naturally-occurring NS5A RAS with high resistance level (> 100X resistance fold-change). In NS5A inhibitor-naïve patients, NS5A RAS testing accompanied by treatment optimization cannot increase treatment response more than 2%-3%, while in NS5A inhibitor-experienced patients, > 75% are found to have NS5A RASs > 100X and NS5A RAS testing in this group of patients seems to be reasonable. This editorial will address the debate on the application of NS5A RAS testing and will discuss if the NS5A RAS testing has any role in clinical management of hepatitis C.

Key words: Direct-acting antiviral agent; Hepatitis C; NS5A; Resistance; Treatment

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Hepatitis C virus resistance to NS5A inhibitors
is one of the main problems of treatment with NS5A inhibitors. While the treatment of NS5A inhibitor-naive patients is feasible and efficient, retreatment of NS5A inhibitor-experienced patients is challenging. In the context of failure following treatment with NS5A-containing regimens, NS5A resistance-associated substitution testing can help in clinical decision-making, while the usefulness of baseline NS5A resistance-associated substitution testing in NS5A inhibitor-naive patients is in question.

**INTRODUCTION**

Antiviral therapy of hepatitis C virus (HCV) infection has been the mainstay of hepatitis C management since application of conventional interferon (IFN) was introduced as the first HCV antiviral agent in 1990s[1,2]. HCV antiviral therapy has transformed greatly over time, from use of immunomodulatory agents, such as IFN, to use of direct-acting antiviral agents (DAAs), such as NS3 protease inhibitors, NS5A inhibitors and NS5B polymerase inhibitors[1]. While the IFN-based regimens result in suboptimal (30%-70%) virologic response, the DAA-based all-oral regimens have efficacy of > 95% in most patient groups[3-5]. Moreover, the treatment response to IFN-based regimens was modified by a large number of different host and virus parameters, such as age, sex, host genetics, liver fibrosis, HCV ribonucleic acid (RNA) level, HCV genotype, variations in HCV genes, etc[3,6,7].

On the other hand, with an increase of response rate to the DAA-based regimens, the modifiers of treatment response have been limited to few parameters, including cirrhosis, history of previous treatment (especially failure with DAA-based regimens), and finally naturally-occurring and DAA-selected resistance-associated substitutions (RASs)[8,9]. Currently, in most of the approved regimens for treatment of HCV infection, NS5A inhibitors are one of the components of the combination therapy with DAs. The currently available and approved NS5A inhibitors are ledipasvir (LDV), daclatasvir (DCV), ombitasvir, elbasvir, velpatasvir (VEL) and pibrentasvir (PIB). In the context of treatment with NS5A inhibitor-containing regimens, the NS5A RAS is one of the baseline predictors of treatment response and, also, the major finding after treatment failure with these regimens[6,10].

**NS5A RASs**

Among the nonstructural proteins of HCV, the roles of NS5A protein are not fully known yet; however, it has been found that NS5A binds the RNA-dependent RNA polymerase NS5B and modulates RNA-dependent RNA polymerase activity[11]. The inhibitory activity of NS5A inhibitors on replication of HCV shows the pivotal role of NS5A protein in replication of HCV. The substitutions in the amino acid sequence of NS5A protein causing decreased binding of NS5A inhibitor molecules to NS5A protein can be selected under pressure of the treatment with NS5A inhibitors and subsequently decrease the inhibitory activity of NS5A inhibitors[12].

Generally, the NS5A amino acid substitutions causing > 2.5 resistance fold-change are considered as NS5A RASs. A subset of these NS5A RASs cause > 100 resistance fold-change, and are considered NS5A RASs > 100X[13]. It is worth noting that the resistance fold-change should be defined with consideration to the HCV genotype and subtype (i.e., 1a, 1b, 3a, etc.), NS5A inhibitor type (i.e., LDV, DCV, VEL, etc.) and also the specific amino acid substitution (i.e., Y93H, Y93F, Y93L, etc.). The NS5A RASs are observed as naturally-occurring substitutions in a proportion (< 10% to > 50%) of NS5A inhibitor-naive patients[13-16]. The rate of detection of NS5A RASs is determined mainly by HCV genotypes and subtypes, and by the method for detection of NS5A RASs (i.e., deep sequencing vs Sanger sequencing)[17,18]. Among patients with NS5A RASs, only a small number (< 5% of NS5A inhibitor-naive patients) of patients harbor isolates with naturally-occurring NS5A RASs > 100X.

The main finding regarding the prevalence of RASs in NS5A inhibitor-naive patients with HCV genotype-1 (HCV-1) is the higher prevalence of NS5A RASs in patients with HCV-1b than in those with HCV-1a[19,20]. In the study by Dietz et al[9], the prevalence of NS5A RASs was 7.1% in patients with HCV-1a infection and 17.6% in those with HCV-1b infection. These NS5A RASs could be found at different levels of a mixed population of the mutated and wild-type viruses[21,22]. In NS5A inhibitor-experienced patients, especially those who have undergone a complete course of 12-wk or > 12-wk treatment, DAA-selected NS5A RASs are observed in > 75% of patients following treatment failure[10,23-25]. Most of these patients with failure to NS5A inhibitor-containing regimens harbor isolates with NS5A RASs > 100X[24,26]. Unfortunately, these DAA-selected NS5A RASs are persistent and they are observed even in the follow-up, 96 wk after treatment failure[27].

The impact of naturally-occurring baseline NS5A RASs has been assessed in many studies. These studies showed the impact of NS5A RASs on treatment response to NS5A inhibitor-containing regimens including LDV/sofosbuvir[22,28], grazoprevir/elbasvir[28,31], ombitasvir/paritaprevir/ritonavir[29] and DCV/asunaprevir[30]; however, treatment with regimens containing the second-generation NS5A inhibitors with medium resistance barrier, including sofosbuvir/VEL[26,32] and glecaprevir/PIB[33], was either not impacted or only minimally modified by the NS5A RASs. In terms of HCV genotypes, it seems that the treatment of patients with HCV-3 infection...
using first-generation NS5A inhibitors is more influenced by NS5A RASs than that of patients with HCV-1 infection using same NS5A inhibitor\textsuperscript{13,26}. This finding can be a result of different resistance fold-change of NS5A RASs by HCV genotypes with higher resistance fold-change for NS5A RASs in HCV-3 isolates than that for NS5A RASs in HCV-1 isolates\textsuperscript{34}. Finally, it can be concluded that the higher response rate observed with the optimized treatment using a second-generation NS5A inhibitor with higher resistance barrier (\textit{i.e.}, VEL, PIB, etc.) effectively inhibiting NS5A protein of all HCV genotypes (pan-genotypic regimen) results in a lower chance for observation of treatment response modification by NS5A RASs.

With the knowledge that most of the patients with failure following treatment with NS5A inhibitor-containing regimens harbor NS5A RASs, especially those which confer a high level of resistance, the impact of these DAA-selected NS5A RASs on the efficacy of retreatment were evaluated in a small number of studies; the results showed that NS5A RASs are prominent treatment response predictors, especially when the regimen of the retreatment was not intensified or optimized for eradication of the virus\textsuperscript{35,36}.

**TESTING RESISTANCE TO NS5A INHIBITORS: WHEN AND HOW?**

There is a great debate on the application and usefulness of NS5A RAS testing prior to treatment. Generally, NS5A RAS testing can be considered under two different conditions: (1) prior to treatment with NS5A inhibitor-containing regimens harbor NS5A RASs, especially those which confer a high level of resistance, the impact of these DAA-selected NS5A RASs on the efficacy of retreatment were evaluated in a small number of studies; the results showed that NS5A RASs are prominent treatment response predictors, especially when the regimen of the retreatment was not intensified or optimized for eradication of the virus\textsuperscript{35,36}.

Currently, there are services available for NS5A RAS testing in diagnostic laboratory centers. These services are based on Sanger direct population sequencing or deep sequencing using next-generation sequencing platforms. The main difference between these two available technologies is the limit of detection of the RAS (mutated nucleotide) among the population of the virus without the RAS (wild-type nucleotide). Sanger sequencing can detect the NS5A RASs comprising 20%-30% of the whole population of the virus, while deep sequencing can even detect NS5A RASs comprising < 1% of the whole HCV population. It figures that deep sequencing is much more advanced for detection of NS5A RASs than Sanger sequencing; however, it was found that a small (< 10%-20% of the whole genetic pool of virus) population of HCV with RAS in a patient has no or minimal impact on treatment success\textsuperscript{21,22,37}. With this finding, it seems that in the clinical management of hepatitis C, the NS5A RAS testing using Sanger sequencing is reasonable, and the reports of NS5A RAS testing using deep sequencing methods should be accompanied by the percentage of the NS5A RAS in the whole virus population.

**CONCLUSION**

DAA-based treatment of HCV is one of the greatest recent achievements in the field of hepatology and liver diseases, making hepatitis C a curable disease; however, the main problem with most of the targeted therapies is resistance. With a combination of NS5A inhibitor with an NS5B polymerase inhibitor and/or an NS3 protease inhibitor, the problem of HCV resistance has been mostly resolved in DAA-naive patients and only a small (< 5%) population of treated patients relapsing after treatment termination. While pretreatment NS5A RAS testing cannot help in management of DAA-naive patients, it can help in treatment decision-making for patients with failure to NS5A inhibitor-containing regimens. Currently, with the introduction of second-generation NS5A inhibitors, VEL and PIB, and the upcoming NS5A inhibitors in the pipeline with a high barrier to resistance, the problem of resistance to NS5A inhibitors is going to fade. However, unsolved concerns remain, such as transmission of NS5A RASs in populations with high-

Sharafi H \textit{et al.} Hepatitis C resistance to NS5A inhibitors
risk behaviors, including people who inject drugs, which should be considered by clinicians and researchers carefully.

REFERENCES

1. **Hesamizadeh K**, Sharafi H, Rezaee-Zavareh MS, Behnava B, Alavian SM. Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. *Hepat Mon* 2016; 16: e37089 [PMID: 27275164 DOI: 10.5812/hepatmon.37089]

2. **Strader DB**, Seeff LB. A brief history of the treatment of viral hepatitis C. *Clin Liver Dis* 2012; 1: 6-11 [DOI: 10.1002/clld.1]

3. **Behnava B**, Sharafi H, Keshvari M, Pouryasin A, Mehmoush L, Salimi S, Karimi Elizee P, Ghazimoghaddam M, Alavian SM. The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C. *Hepat Mon* 2016; 16: e32703 [PMID: 27110259 DOI: 10.5812/hepatmon.32703]

4. **Alavian SM**, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimib Daryani N, Merat S, Mohraz M, Mardani M, Fattahi MR, Poustchi H, Nikbin M, Nabavi M, Adibi P, Ziaee M, Behnava B, Rezaee-Zavareh MS, Colombo M, Massoumi H, Bizi R, Eghtesad B, Amiri M, Namvar A, Hesamizadeh K, Malekzadeh R. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. *Hepat Mon* 2016; 16: e40959 [PMID: 27799966 DOI: 10.5812/hepatmon.guideline]

5. **Sharafi H**, Nikbin M, Alavian SH, Behnava B, Alavian SM. Efficacy and Safety of Generic Sofosbuvir/Ledipasvir Fixed-Dose Combination in Iranian Patients with Chronic Hepatitis C Virus Infection. *Hepat Mon* 2017; 17: e12216 [DOI: 10.5812/
Chen ZW 2017; 18: 91 - 98 [PMID: 27292693 DOI: 10.1016/j.jhep.2016.11.022]

Shirato Y, Luo H, Qin W, Kaneko S, Yamashita T, Kobayashi K, Murakami S. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. J Biol Chem 2002; 277: 11149-11155 [PMID: 11801599 DOI: 10.1074/jbc.M111392200]

Kwon HJ, Xing W, Chan K, Niedziela-Majka A, Brendza KM, Kirschberg T, Dato D, Link JO, Cheng G, Liu X, Sakowicz R. Direct binding of ledipasvir to HCV NSSA: mechanism of resistance to an HCV antiviral agent. PLoS One 2015; 10: e0122844 [PMID: 25856426 DOI: 10.1371/journal.pone.0122844]

Zeuzem S, Mizokami M, Pankow S, Mangia A, Han KH, Martin R, Svarovskaia E, Dyrvoy-Sobol H, Doehle BP, Breda C, Yan C, Brainard DM, Knoss S, McHutchison JG, Miller MD, Mo H, Chuan WL, Jacobson I, Dore GJ, Sulkowski MS. NSSA resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. J Hepatol 2017; 66: 910-918 [PMID: 28108232 DOI: 10.1016/j.jhep.2017.01.007]

Sarrazin C, Dyrvoy-Sobol H, Svarovskaia E, Doehle BP, Pang PS, Chuan SM, Ma J, Ding X, Afadhil NH, Kodwley KV, Gane EJ, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H, Cao M, Walsh J, Burton A, Kiehlberg H, Kuhlmann V, Tournier-Larribe ME, Brouiller P, Abravanel F, Baseline and post-treatment hepatitis C NSSA resistance in relapsed patients from a multicentric real-life cohort. Antivir Ther 2017 [PMID: 28730994 DOI: 10.3851/IMP3184]

Starace M, Minichini C, De Pascaletti S, Macera M, Occhiello E, Livi E, Massimino S, Tambone I, Iovinella V, Martini S, Masarone M, Fontanella L, Masiello A, Sagnelli E, Punzi R, Salomone Megna M, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini Afdhal NH, Kowdley KV, Lawitz E, Brainard DM, Miller MD, Mo H, Svarovskaia E, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O'Leary JG, Shafran SD, Zeuzem S. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol 2018; 68: 895-903 [PMID: 29221887 DOI: 10.1016/j.jhep.2017.11.032]

Wyles D et al. Hepatitis C virus NSSA inhibitors: mining the GenBank HCV genome data. Sci Rep 2016; 6: 20310 [PMID: 26842909 DOI: 10.1038/srep20310]
Sharafi H et al. Hepatitis C resistance to NS5A inhibitors

JM. Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study. *Clin Infect Dis* 2018; 66: 1013-1018 [PMID: 29077964 DOI: 10.1093/cid/cix916]

30 Bruchfeld A, Roth D, Martin P, Nelson DR, Pol S, Londoño MC, Monsour H Jr, Silva M, Hwang P, Arduino JM, Robertson M, Nguyen BY, Wahl J, Barr E, Greaves W. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. *Lancet Gastroenterol Hepatol* 2017; 2: 585-594 [PMID: 28576451 DOI: 10.1016/S2468-1253(17)30116-4]

31 Gane E, Nahass R, Luketis V, Asante-Appiah E, Hwang P, Robertson M, Wahl J, Barr E, Haber B. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naive, noncirrhotic HCV genotype 3-infected patients. *J Viral Hepat* 2017; 24: 895-899 [PMID: 28470815 DOI: 10.1111/jvh.12719]

32 von Felden J, Vermehren J, Ingiliz P, Mauss S, Lutz T, Simon KG, Busch HW, Baumgarten A, Schewe K, Hueppe D, Boesecke C, Rockstroh JK, Daemmer M, Luebbe N, Timm J, Schulze Zur Wiesch J, Sarrazin C, Christiansen S. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection. *Aliment Pharmacol Ther* 2018; 47: 1288-1295 [PMID: 29536554 DOI: 10.1111/apt.14592]

33 Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, Irvin M, Xie W, Fu B, Burroughs M, Redman R, Kumada H, Chayama K, Collins P, Matias-T. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. *Antimicrob Agents Chemother* 2018; 62: pii: e02217-17 [PMID: 29180522 DOI: 10.1128/AAC.02217-17]

34 Gottwein JM, Pham LV, Mikkelsen LS, Ghanem L, Ramirez S, Scheel TKH, Carlsen THR, Buhl J. Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants. *Gastroenterology* 2018; 154: 1435-1448 [PMID: 29274866 DOI: 10.1053/j.gastro.2017.12.015]

35 Lawitz E, Flamm S, Yang JC, Pang PS, Zhu Y, Svarovskaia E, McHutchison JG, Wyles D, Pockros P. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. *J Hepatol* 2015; 62: S192 [DOI: 10.1016/S0168-8278(15)30012-X]

36 Kawakami Y, Ochi H, Hayes CN, Imamura M, Tsuge M, Nakahara T, Katamura Y, Kohno H, Kohno H, Tsuji K, Takaki S, Mori N, Honda Y, Arakaki K, Takahashi S, Kira S, Tamura T, Masuda K, Nakamura T, Kikkawa M, Chayama K. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study. *J Gastroenterol* 2018; 53: 548-556 [PMID: 28815329 DOI: 10.1007/s00535-017-1380-8]

37 Ide T, Eguchi Y, Harada M, Ishii K, Morita M, Morita Y, Sugiyama G, Fukushina H, Yano Y, Noguchi K, Nakamura H, Hiasato M, Kumemura H, Shirachi M, Iwane S, Okada M, Honma Y, Arinaga-Hino T, Miyajima I, Ogata K, Kawanishi R, Amano K, Kagawachi T, Kuromatsu R, Torimura T; DAA Multicenter Study Group. Evaluation of Resistance-Associated Substitutions in NSSA Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. *PLoS One* 2016; 11: e0163884 [PMID: 27684567 DOI: 10.1371/journal.pone.0163884]

P- Reviewer: Hann HW, Jarcuska P, Inoue K, Quelleri J S- Editor: Dou Y L- Editor: A E- Editor: Tan WW
